Search

ized either to treatment group A: Tac (0.01-0.03 mg/kg/d iv – 0.05-0.3 mg/kg/d po) or group B: CsA (1-3 mg/kg/d iv – 2-8 mg/kg/d po). Stratification for cystic fibrosis was performed. MMF (1-4 mg/d) was administered according to trough levels. No induction therapy was given. Intention to treat analysis was performed in switched patients. Results: There was no difference in demographic data between groups. 3 of 125 patients in the Tac group and 45 of 124 patients in the CsA group were switched to another immunosuppressive regimen. Data of 219 patients were available at time of abstract submission. 12 patients in the Tac group and 21 patients in the CsA group developed BOS (10.7% vs. 19.6%, p 0.066). Incidence of acute rejection was 66.9% in the Tac group and 72.9% in the CsA group (p 0.157). 1 and 3 year survival rates were not different (83.9% Tac vs. 86.9% CsA, p 0.7271 and 78.6% Tac vs. 81.3% CsA, p n.s.). Incidence of bacterial, viral and fungal infection and renal failure was similar in both groups (p n.s.). Conclusions: Both regimens have an excellent immunosuppressive potential and offer a similar safety profile with excellent one and three year survival rates. There was a clear trend towards less BOS in the Tac group. Number of acute rejections was similar in both groups as well as incidence of infections and renal failure. Final data of all 249 patients will be presented at the conference.